Pharmacological activities and side effects of plafibride.
This paper reports on pharmacological properties of N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethyl-urea (plafibride, ITA 104) and its possible side effects. This work was carried out on CNS, ANS and PNS, cardiovascular system, respiratory and gastroenteric apparatus as well as anti-inflammatory activity and gastric tolerance. The most evident secondary effects were: a certain sedation, as a light tranquillizing agent, a hypothermic effect when it was administered at high doses, a certain beta-blocking and antiarrhythmic activity probably due to its local anaesthetic action. All the side effects appeared at high doses, much higher than the therapeutic ones.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001341:Autonomic Nervous System / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects*; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D004064:Digestive System / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D010525:Peripheral Nerves / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002995:Clofibric Acid; C016894:plafibride; D002994:Clofibrate